Comparison of Kinetics of Antibody Avidity and IgG Subclasses' Response in Patients with COVID-19 and Healthy Individuals Vaccinated with the BNT162B2 (Comirnaty, Pfizer/BioNTech) mRNA Vaccine.

Autor: Rastawicki W; Department of Bacteriology and Biocontamination Control, National Institute of Public Health NIH-National Research Institute, 00-791 Warsaw, Poland., Gierczyński R; Department of Bacteriology and Biocontamination Control, National Institute of Public Health NIH-National Research Institute, 00-791 Warsaw, Poland., Zasada AA; Department of Sera and Vaccines Evaluation, National Institute of Public Health NIH-National Research Institute, 00-791 Warsaw, Poland.
Jazyk: angličtina
Zdroj: Viruses [Viruses] 2023 Apr 14; Vol. 15 (4). Date of Electronic Publication: 2023 Apr 14.
DOI: 10.3390/v15040970
Abstrakt: There are limited reports concerning the levels of antibodies in IgG subclasses and the avidity of IgG, which is the functional strength with which an antibody binds to an antigen in serum samples obtained at different times after infection or vaccination. This study investigated the kinetics of antibody avidity and the IgG antibody response within IgG1-IgG4 subclasses in individuals vaccinated with the BNT162B2 mRNA vaccine and in COVID-19 patients. Serum samples were collected from individuals vaccinated with three doses of the BNT162B2 (Comirnaty, Pfizer/BioNTech) vaccine and from unvaccinated COVID-19 patients. This study revealed that IgG1 was a dominating subclass of IgG both in COVID-19 patients and in vaccinated individuals. The level of IgG4 and IgG avidity significantly increased 7 months after the first two doses of the vaccine and then again after the third dose. IgG2 and IgG3 levels were low in most individuals. Investigating IgG avidity and the dynamics of IgG subclasses is essential for understanding the mechanisms of protection against viral infections, including COVID-19, especially in the context of immunization with innovative mRNA vaccines and the possible future development and application of mRNA technology.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje